Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Puma Biotechnology Inc (NASDAQ: PBYI) closed at $5.01 down -12.65% from its previous closing price of $5.73. In other words, the price has decreased by -$12.65 from its previous closing price. On the day, 1.58 million shares were traded. PBYI stock price reached its highest trading level at $6.06 during the session, while it also had its lowest trading level at $4.81.
Ratios:
For a deeper understanding of Puma Biotechnology Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.70. For the most recent quarter (mrq), Quick Ratio is recorded 1.62 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.10.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 18 ’25 when Cesano Alessandra sold 27,000 shares for $3.37 per share. The transaction valued at 90,909 led to the insider holds 41,850 shares of the business.
Cesano Alessandra bought 27,000 shares of PBYI for $90,909 on Jul 18 ’25. On Jul 08 ’25, another insider, NOUGUES MAXIMO F, who serves as the Chief Financial Officer of the company, sold 5,587 shares for $3.53 each. As a result, the insider received 19,739 and left with 208,164 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 252105360 and an Enterprise Value of 205311472. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.11, and their Forward P/E ratio for the next fiscal year is 15.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 2.38. Its current Enterprise Value per Revenue stands at 0.862 whereas that against EBITDA is 3.58.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.37, which has changed by 0.8351648 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $5.81, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is 38.27%, while the 200-Day Moving Average is calculated to be 55.70%.
Shares Statistics:
For the past three months, PBYI has traded an average of 482.15K shares per day and 1320590 over the past ten days. A total of 49.89M shares are outstanding, with a floating share count of 37.73M. Insiders hold about 24.71% of the company’s shares, while institutions hold 56.91% stake in the company. Shares short for PBYI as of 1753920000 were 2784330 with a Short Ratio of 5.77, compared to 1751241600 on 2633554. Therefore, it implies a Short% of Shares Outstanding of 2784330 and a Short% of Float of 6.529999999999999.
Earnings Estimates
The dynamic stock of Puma Biotechnology Inc (PBYI) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.36, with high estimates of $0.36 and low estimates of $0.36.
Analysts are recommending an EPS of between $0.7 and $0.7 for the fiscal current year, implying an average EPS of $0.7. EPS for the following year is $0.65, with 1.0 analysts recommending between $0.65 and $0.65.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $51M this quarter.It ranges from a high estimate of $51M to a low estimate of $51M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $80.5MFor the next quarter, 1 analysts are estimating revenue of $66.6M. There is a high estimate of $66.6M for the next quarter, whereas the lowest estimate is $66.6M.
A total of 1 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $216M, while the lowest revenue estimate was $216M, resulting in an average revenue estimate of $216M. In the same quarter a year ago, actual revenue was $230.5MBased on 1 analysts’ estimates, the company’s revenue will be $218M in the next fiscal year. The high estimate is $218M and the low estimate is $218M.
